Clinical trials: Placebo Response
Generalized Anxiety Disorder
A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD.
- Trial name
- CAR aGAD Ph 2 (NCT04965272)
- Testing
- Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day
- Where
- 36 sites in United States
- Sponsor
- AbbVie
Healthy
A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model
An endotoxin challenge will be administered to healthy subjects to induce production of inflammatory markers. An investigational drug or placebo will be administered prior to the endotoxin challenge to assess the effect of the…
- Trial name
- POM (NCT01965600)
- Testing
- PF-06282999, LPS
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Pfizer
Elevated Intraocular Pressure
A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)
Double-masked, randomized, multi-center, placebo-controlled parallel-comparison of AR-12286.
- Trial name
- NCT00902200
- Testing
- AR-12286, AR-12286 vehicle
- Where
- 8 sites in United States
- Volunteers
- 89 people
- Sponsor
- Aerie Pharmaceuticals
Amyloid Plaque, Beta-Amyloid
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.
- Conditions
- Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease
- Trial name
- NCT05462106
- Testing
- ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a
- Where
- 26 sites in United States, Spain and 1 more
- Volunteers
- 304 people
- Sponsor
- AC Immune SA
Pressure Ulcers
Study of Thymosin Beta 4 in Patients With Pressure Ulcers
The purpose of this study is to evaluate the safety, tolerability and effectiveness of Thymosin Beta 4 administered topically in patients with Pressure Ulcers
- Trial name
- NCT00382174
- Testing
- Thymosin Beta 4
- Where
- 12 sites in United States
- Volunteers
- 72 people
- Sponsor
- RegeneRx Biopharmaceuticals, Inc.
Primary Biliary Cholangitis
ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid…
- Trial name
- NCT03602560
- Testing
- seladelpar 5-10 mg, seladelpar 10 mg
- Where
- 156 sites in United States, Argentina and 21 more
- Volunteers
- 265 people
- Sponsor
- Gilead Sciences
Rheumatoid Arthritis
A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy
This study will evaluate the efficacy and safety of ocrelizumab, compared to placebo, in patients with active rheumatoid arthritis who have an inadequate response to methotrexate therapy.
- Trial name
- FEATURE (NCT00673920)
- Testing
- Methotrexate, Ocrelizumab
- Volunteers
- 314 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
A Study Evaluating the Efficacy and Safety of CKD-506 in Adult Subjects With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate
The primary objective of this study is to evaluate the effects of CKD-506 on signs and symptoms of RA in subjects with moderate-to-severe RA who are inadequate responders to methotrexate.
- Trial name
- NCT04204603
- Testing
- CKD-506
- Where
- 38 sites in Czechia, Georgia and 3 more
- Volunteers
- 122 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Moderate-to-severe Atopic Dermatitis
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable
The primary objective of this study is to investigate the efficacy of nemolizumab administered in combination with topical background therapy (topical corticosteroids [TCS] with or without topical calcineurin inhibitors [TCI]) in…
- Trial name
- NCT05056779
- Testing
- Nemolizumab
- Sponsor
- Galderma R&D
Hypertriglyceridemia
Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia
The purpose of this study is to evaluate the dose/response pharmacodynamic effects of ISIS ApoC-III Rx vs. Placebo on fasting total apoC-III levels.
- Trial name
- NCT01529424
- Testing
- ISIS apoC-III Rx
- Where
- 7 sites in United States, Canada
- Volunteers
- 89 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Covid19
Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a
VBI-2902a and VBI-2905a are investigational vaccine candidates that use enveloped virus-like particle (eVLP) expression of a modified version of the SARS-CoV-2 spike (S) glycoprotein and are designed to induce neutralizing…
- Trial name
- NCT04773665
- Testing
- VBI-2902a, VBI-2905a
- Where
- 4 sites in Canada
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Crohn Disease
Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease
The purpose of this study is to evaluate if Leukine can induce clinical response or remission in patients with Crohn's disease.
- Trial name
- NCT00295165
- Testing
- Sargramostim (Leukine)
- Where
- 111 sites in United States, Australia and 9 more
- Volunteers
- 33 people
- Sponsor
- Genzyme, a Sanofi Company
Asthma
Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects
The aim of the present study is to investigate whether the effects of salmeterol in combination with fluticasone propionate on blood markers of airway inflammation are maintained after chronic dosing and whether the effect is…
- Trial name
- NCT00517634
- Testing
- FP, SFC
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
The purpose of this study is to determine the efficacy and safety of three different Tregalizumab doses in combination with Methotrexate (MTX) in subjects who have active rheumatoid arthritis and an inadequate response to MTX…
- Trial name
- 986 (NCT01999192)
- Testing
- Tregalizumab
- Where
- 84 sites in United States, Bulgaria and 12 more
- Volunteers
- 321 people
- Sponsor
- Biotest
Rheumatoid Arthritis
Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
The purpose of this study is to investigate the efficacy and safety of Hydroxytriptolide(LTS) in active rheumatoid arthritis patients with an inadequate response to methotrexate.
- Trial name
- T8 (NCT02202395)
- Testing
- LTS 0.25mg, LTS 0.5mg, LTS 1.0mg
- Where
- 5 sites in China
- Volunteers
- 120 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Insomnia, Depressive Disorder, Major
A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder
The purpose of this study is to evaluate subjective sleep efficacy in subjects with insomnia related to major depressive disorder.
- Trial name
- NCT00368030
- Testing
- Eszopiclone
- Where
- 65 sites in United States
- Volunteers
- 545 people
- Sponsor
- Sumitomo Pharma America, Inc.
Essential Hypertension
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension
The primary objective of the study is to evaluate the safety and tolerability of single ascending doses of Vasomera (PB1046) administered subcutaneously in adult subjects with Stage 1 or Stage 2 essential hypertension.
- Trial name
- NCT01523067
- Testing
- Vasomera (PB1046), 0.9% Sodium Chloride
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Ocular Hypertension, Open Angle Glaucoma
Study of AR-13324 in Patients With Elevated Intraocular Pressure
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days.
- Trial name
- NCT01528787
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 11 sites in United States
- Volunteers
- 85 people
- Sponsor
- Aerie Pharmaceuticals
Hyperlipidemias, Dyslipidemias
Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)
This study will investigate the safety and tolerability of SLN360 in patients with elevated Lp(a).
- Conditions
- Hyperlipidemias, Dyslipidemias, Elevated Lp(a)
- Trial name
- NCT04606602
- Testing
- SLN360
- Where
- 8 sites in United States, Australia and 2 more
- Volunteers
- 70 people
- Sponsor
- Silence Therapeutics plc
Rheumatoid Arthritis
Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)
The objective of this trial is to investigate the efficacy (American College of Rheumatology 20% : ACR20) superiority of two dose regiments of CDP870 versus placebo in combination with MTX in active RA patients who have an…
- Trial name
- NCT00791999
- Testing
- CDP870 400mg, CDP870 200mg, CDP870 100mg
- Where
- 8 sites in Japan
- Volunteers
- 316 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.